Wedbush Reiterates Underperform, $5 PT On Dendreon

In a note out this morning, Wedbush reiterated a buy rating and $5 price target on biotech firm Dendreon DNDN, implying significant downside from where the shares currently trade. The company announced it's selling its royalty interest in Victrelis for $125 million. “While a positive for the company's balance sheet in the near-term, we still estimate that DNDN will have to access the capital markets, now in mid:13, rather than YE:12. Given our estimates for DNDN's cash burn, this move delays a share offering by 6 months. Taking into account this additional cash, our cash burn estimate over the next 6 quarters is ~$315M, which would reduce the company's cash balance to $218M by Q2:13,” Wedbush said in the note.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorNewsPrice TargetReiterationAsset SalesFDAPre-Market OutlookMarketsAnalyst RatingsTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!